



argenx to host conference call & webcast to report fourth quarter business update and full year 2018 financial results on February 28, 2019

February 21, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, February 28, 2019 at 3:00 pm CET (9:00 am ET) to discuss its 2018 financial results and provide a fourth quarter business update.

To participate in the conference call, please select your phone number below and use the confirmation code **9795988**. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking [here](#).

A replay of the webcast will also be available at the argenx website.

Dial-in numbers:

Please dial in 5–10 minutes prior to 3 p.m. CET/ 9 a.m. ET using the number and conference ID below.

Confirmation Code: **9795988**

Belgium	+32 (0)2 400 9874
Belgium	0800 48740
France	+33 (0)1 767 00794
France	0805 103028
Netherlands	+31 (0)20 714 3545
Netherlands	0800 0249557
United Kingdom	+44 (0)844 571 8892
United Kingdom	0800 376 7922
United States	+1 (631) 510 7495
United States	+1 (866) 966 1396

A question and answer session will follow the presentation of the results. Go to www.argenx.com to access the live audio webcast. The archived webcast will also be available (90 days) for replay shortly after the close of the call from the “Downloads” section of the argenx website.

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx's ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE Antibody™ Platform, based on

the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.

www.argenx.com